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Abstract
Background: Psoriatic arthritis (PsA), an inflammatory musculoskeletal disease, develops in approximately 30% of
patients with psoriasis. Previously, chemokine (C-X-C motif) ligand 10 (CXCL10) was identified as a predictive biomarker
of PsA in patients with psoriasis and was reduced after development of PsA. The purpose of the present study was to
explore messenger RNA (mRNA) and protein expression of CXCL10 and its receptor, chemokine (C-X-C motif) receptor
3 (CXCR3), in the joints of patients with PsA to gain insight into their role in the pathogenesis of the disease.
Methods: Sera from 47 patients with PsA and 33 healthy control subjects were compared for expression of CXCL10 by
Luminex assay. Synovial fluid (SF) was obtained from patients with PsA (n = 40), osteoarthritis (OA; n = 14), gout (n = 8),
and rheumatoid arthritis (RA; n = 11) during clinical care. SF mRNA and protein expression of CXCL10, interleukin-17A
(IL-17A), CXCR3, TBX21, RORC and/or interferon γ (IFNγ) were compared among the above-mentioned disease groups, as
well as in paired SF and serum samples from patients with PsA using real-time polymerase chain reaction and Luminex
assays, respectively.
Results: Serum CXCL10 was significantly higher in patients with PsA than in control subjects (p = 0.0007). CXCL10,
IL-17A, and TBX21 expression were elevated in SF cells of patients with PsA compared with those of patients with
OA and gout, but not those of patients with RA. CXCR3 and RORC were elevated in PsA SF cells compared with all
other patient groups. Concordant results were obtained for CXCL10 and IL-17A protein expression. IFNγ was elevated
in PsA SF compared with OA SF (p = 0.015). CXCL10 protein expression was substantially increased in SF (median
7283.9 pg/ml, interquartile range [IQR] 1330–10,362 pg/ml) compared with paired serum samples (median 282.06,
IQR 180.7–395.8 pg/ml; p = 0.001), whereas IFNγ was significantly reduced (SF median 6.03 pg/ml, IQR 4.47–8.94 pg/ml;
versus serum median 23.70 pg/ml, IQR 3.2–104.6 pg/ml; p = 0.001).
Conclusions: CXCL10 may have an important etiological role in PsA that is analogous to that in RA, and it is a candidate
biomarker to distinguish PsA from healthy individuals and from patients with OA and gout.
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Background
Psoriatic arthritis (PsA) is an immune-mediated inflam-
matory musculoskeletal disease that affects approximately
30% of patients with psoriasis [1–3]. PsA is associated
with joint, ligament, and tendon pain, stiffness, and swell-
ing that lead to damage to the peripheral, axial, and enthe-
seal structures, resulting in reduced quality of life and life
expectancy for the affected individuals [4, 5]. For individ-
uals affected by PsA, the initial screening and diagnosis
are often done by family physicians or dermatologists.
Studies have shown that approximately 50% of cases of
PsA are currently undetected in patients with psoriasis
[6, 7]. Physicians with limited experience in this area
may find it difficult to diagnose PsA, which can be con-
fused with other rheumatologic conditions such as
osteoarthritis (OA) or gout. The identification of bio-
markers that distinguish PsA from the general popula-
tion and/or other rheumatologic diseases can aid in the
development of tools for family physicians and derma-
tologists to better identify patients with PsA.
We previously performed microarray analysis to iden-
tify transcriptomic biomarkers that distinguish patients
with PsA from those with psoriasis without PsA (PsC).
We found that chemokine (C-X-C motif ) ligand 10
(CXCL10) was upregulated in patients with PsA com-
pared with those with PsC [8]. CXCL10 is a ligand for
the chemokine (C-X-C motif ) receptor 3 (CXCR3), and
their interaction is responsible for recruitment of acti-
vated T helper (Th) cells and natural killer (NK) cells to
the site of inflammation [9, 10]. In acute and chronic in-
flammation, leukocyte infiltration is regulated by both
exogenous and endogenous factors, including cytokines,
chemokines, and proteases [9]. It is generally accepted
that the main endogenous inducer of CXCL10 is inter-
feron γ (IFNγ); however, acting in conjunction with
tumor necrosis factor α (TNFα), a synergic effect has
been reported in several cell types, including leukocytes,
epithelial cells, endothelial cells, and fibroblasts [11, 12].
Secreted CXCL10 proteins then recruit Th1 lymphocytes
expressing CXCR3 to the sites of inflammation [11–13].
Together, this forms a positive feedback loop of inflam-
mation and cell proliferation.
We have also previously shown that serum levels of
CXCL10 were elevated in patients with psoriasis who
subsequently developed PsA compared with those who
did not develop PsA, and this was independent of clin-
ical predictors of PsA [14]. Thus, CXCL10 may be im-
portant in the pathogenesis of PsA and may be a useful
predictor of PsA in patients with psoriasis. CXCL10
levels in serum also dropped after the development of
PsA in these patients, possibly as a result of an accumu-
lation of activated lymphocytes in target tissues [14].
The objective of the present study was to further ex-
plore CXCL10 expression in serum and synovial fluid
(SF) of patients with PsA. First, we compared serum
CXCL10 expression in patients with PsA and in healthy
control subjects, as well as SF CXCL10 expression in pa-
tients with PsA, OA, rheumatoid arthritis (RA), and
gout. Next, we compared paired synovial and serum ex-
pression of CXCL10. In addition, the expression of
CXCR3, IFNγ, and interleukin (IL)-17A, as well as the
Th1- and Th17-specific transcription factors T-bet and
RAR-related orphan receptor γt (RORγt), was measured
to gain insight into the interplay of these molecules with
CXCL10 in disease pathogenesis. The aim of this study




Patients with PsA with available SF samples from the
knee joint were identified from a cohort of patients
followed prospectively from 2004 to 2015 at the Univer-
sity of Toronto PsA clinic. The diagnosis of PsA was
made by a rheumatologist, and the patients satisfied the
ClASsification for Psoriatic ARthritis (CASPAR) criteria
[15]. At baseline and at each 6- to 12-month follow-up
visit, a complete history including demographic and
disease-related features, as well as a physical examin-
ation including skin and musculoskeletal assessments,
was carried out according to a standard protocol.
SF from patients with PsA, gout, and RA was drawn
from knee joints during clinical care. Samples from pa-
tients with OA were obtained during either routine joint
aspiration or full knee replacement surgery. SF samples
were centrifuged and stored in the biobank at −80 °C for
Luminex assays (Luminex, Austin, TX, USA). When cells
were present in SF, cell pellets were further processed
for messenger RNA (mRNA) analysis, as described
below. Samples obtained from SF for Luminex assay and
gene expression experiments are summarized in Fig. 1.
Additionally, serum samples were obtained from 47 pa-
tients with PsA and 33 healthy volunteers. This study
was approved by the University Health Network Re-
search Ethics Board according to the principles of the
Declaration of Helsinki, and all participants provided
written consent.
Multiplex chemokine and cytokine assay
CXCL10, IL-17A, and IFNγ levels in SF were measured
in patients with PsA (n = 40), gout (n = 8), OA (n = 14),
and RA (n = 11) using a multiplex human chemokine/
cytokine magnetic bead panel (EMD Millipore, Billerica,
MA, USA) according to the manufacturer’s instructions.
Serum samples from 11 patients with PsA, paired with SF
drawn at the same visit, were also used to measure
CXCL10, IL-17A, and IFNγ levels. Briefly, the SF or serum
samples (25 μl) were incubated with a chemokine-/
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cytokine-specific capture antibody attached to magnetic
beads. Then a detection antibody was added, followed by
streptadavin-phycoerythrin acting as a reporter molecule.
Data were acquired using the Luminex 200 system (Lumi-
nex, Austin, TX, USA ) and analyzed with Bio-Plex Man-
ager software (Bio-Rad Laboratories, Hercules, CA, USA).
All samples were measured in duplicate, and CXCL10, IL-
17A, and IFNγ levels were quantified in relation to a five-
fold serially diluted standard provided with the kit, using a
five-parameter logistic regression curve.
Gene expression analysis
Whole blood from seven patients with PsA was collected
in Tempus® tubes (Life Technologies, Carlsbad, CA,
USA), and mRNA was extracted according to the manu-
facturer’s instructions. SF cells were collected from 30
patients with PsA, 4 with OA, 6 with gout, and 5 with
RA. The cells were treated with red blood cell lysis buf-
fer and stored in TRIzol® reagent (Life Technologies).
Phenol-chloroform extraction was used to extract total
RNA, and the RNeasy® Mini Kit (Qiagen, Venlo, The
Netherlands) was used to purify it. Reverse transcription
of mRNA was performed using the Maxima First Strand
cDNA Synthesis Kit (Life Technologies). CXCL10,
CXCR3, IL-17A, T-bet (TBX21), and RORγt (RORC)
complementary DNA was amplified with Platinum®
SYBR Green qPCR SuperMix (Life Technologies) using
corresponding forward and reverse primers. Reactions
were measured in triplicate on a 7900HT real-time poly-
merase chain reaction system (Applied Biosystems,
Foster City, CA, USA). Ct values obtained for CXCL10,
CXCR3, IL-17A, TBX21, and RORC were normalized to
GAPDH to generate ΔCt values for each sample. Fold
change between groups was determined by the ΔΔCt
method, where ΔΔCt =mean ΔCtgroup1 −mean ΔCtgroup2
and fold change = 2−ΔΔCt. Values are expressed as 2−ΔCt in
the figures to show trends in gene expression [16].
Statistical analysis
Gene expression differences of CXCL10, CXCR3, IL-17A,
TBX21, and RORC between PsA and the other disease
cohorts (OA, gout, and RA) were determined using Stu-
dent’s t tests on ΔCt values. For the comparison of che-
mokine/cytokine gene expression between SF cells and
whole-blood RNA, paired Student’s t tests were per-
formed. Differences between CXCL10, IL-17A, and IFNγ
protein levels between groups were identified by per-
forming the Wilcoxon signed-rank test for paired SF and
serum samples and the Mann-Whitney U test for com-
parison between patients with PsA and control subjects.
Statistical analysis was performed using the R statistical
software package as well as Prism 5 software (GraphPad
Software, La Jolla, CA, USA). For all the statistical tests
performed, p < 0.05 was accepted as significant.
Results
Patient characteristics
SF samples were obtained from a total of 40 patients
with PsA, 14 with OA, 8 with gout, and 11 with RA.
The demographic and clinical characteristics of patients
with SF samples analyzed by the Luminex assay and the
subset of patients with synovial cells also measured for
gene expression are found in Table 1. Patients with
PsA analyzed by Luminex assay, as well as the subset
also included in the gene expression assay, were sig-
nificantly younger than the entire cohort of patients
Fig. 1 Summary of synovial fluid (SF) samples measured by Luminex assay (protein) and gene expression (messenger RNA). Gene expression was
measured in a subset of patients analyzed with the Luminex assay. CXCL10 Chemokine (C-X-C motif) ligand 10, CXCR3 Chemokine (C-X-C motif)
receptor 3, IFNγ Interferon γ, IL Interleukin, OA Osteoarthritis, PsA Psoriatic arthritis, RA Rheumatoid arthritis
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with OA (p < 0.0001 by one-way analysis of variance).
A significant difference in the proportion of male and
female patients was found (p = 0.003 by Pearson’s chi-
square test). There were no significant differences in
patients who were included in gene expression ana-
lysis as compared with those who were measured only
with the Luminex assay, including the use of systemic
agents such as disease-modifying antirheumatic drugs
and biologic agents. Additionally, there were no sig-
nificant differences in mRNA expression or protein
levels in PsA SF in response to different medication
regimens. It should be noted that detailed clinical data
on patients with RA, gout, and OA were not available
for comparison. Additionally, 47 patients with PsA
(mean age 46 years, 43% males) and 33 healthy control
subjects (mean age 53 years, 42% males) were included
for the comparison of CXCL10 levels in serum.
CXCL10 is elevated in PsA serum
Our first step was to compare serum levels of CXCL10 be-
tween patients with PsA and healthy control subjects. As
shown in Fig. 2, CXCL10 expression was significantly ele-
vated in patients with PsA (median 0.31 ng/ml, interquar-
tile range [IQR] 0.20–0.44 ng/ml) compared with control
subjects (median 0.21, IQR 0.14–0.28 ng/ml, p = 0.0007).
These results support the use of CXCL10 as a biomarker
to distinguish PsA from the general population.
CXCL10, IL-17A, and IFNγ protein levels are elevated in
PsA synovial fluid
Next, cytokine and chemokine protein expression was
measured in SF from 40 patients with PsA, 14 with OA, 8
with gout, and 11 with RA. As shown in Fig. 3, CXCL10
levels (median 5.39 ng/ml, IQR 1.81–9.82 ng/ml) were sig-
nificantly elevated in PsA compared with OA (median
0.83 ng/ml, IQR 0.73–3.38 ng/ml; p = 6 × 10−4) and gout
(median 0.97 ng/ml, IQR 0.80–1.48 ng/ml; p = 0.004). The
same trend was observed for IL-17A, where levels in
PsA SF (median 7.77 pg/ml, IQR 3.26–18.14 pg/ml)
were higher than both OA SF (median 3.20 pg/ml, IQR
1.55–3.20 pg/ml; p = 9.3 × 10−4) and gout SF (median
Table 1 Demographic and clinical characteristics of study subjects with synovial fluid analyzed by Luminex assay and gene
expression

















Male sex 26 (65%) 18 (60%) 3 (25%) 0 (0%) 7 (87.5%) 5 (83.3%) 2 (20%) 0 (0%) 0.0003
Age, yearsb 44.4 (12.9) 45.1 (13.3) 69.1 (11.4) 79.0 (1.4) 61.3 (22.0) 56.5 (23.8) 49.0 (17.5) 52.3 (17.8) <0.0001
Duration of psoriasisc 14 (7.3–21.8) 18 (10–24) – – – – – – 0.584
Duration of PsAc 9 (3–15) 10 (3–15) – – – – – – 0.755
PASIc 1.8 (0.6–4.2) 1.8 (0.6–4.5) – – – – – – 0.959
Number of swollen jointsc,d 2 (1–3) 1 (1–3) – – – – – – 0.834
Number of tender jointsc,d 2 (0–5) 1 (0–3.8) – – – – – – 0.435
Current use of NSAIDs 18 (45%) 12 (40%) – – – – – – 0.676
Current use of DMARDs 17 (43%) 14 (47%) – – – – – – 0.728
Current use of biologics 10 (25%) 9 (30%) – – – – – – 0.642
Abbreviations: DMARD Disease-modifying antirheumatic drug, mRNA Messenger RNA, NSAID Nonsteroidal anti-inflammatory drug, OA Osteoarthritis, PASI Psoriasis
Area Severity Index, PsA Psoriatic arthritis, RA Rheumatoid arthritis
aOne-way analysis of variance or Mann-Whitney U test (continuous variables) or Pearson’s chi-square test (categorical variables)
bMean (SD)
cMedian (interquartile range)
dTender joints were determined clinically in 68 joints, swollen joints in 66 (excluding hips)
Fig. 2 Scatter dot plot of serum chemokine (C-X-C motif) ligand 10
(CXCL10) expression from patients with psoriatic arthritis (PsA; n = 47)
and healthy control subjects (n = 33). The data are presented as log10-
transformed values to better visualize the absolute change in
concentrations. CXCL10 levels were higher in patients with PsA
(median 0.31 ng/ml, interquartile range [IQR] 0.20–0.44 ng/ml) than
in healthy control subjects (median 0.21, IQR 0.14–0.28 ng/ml;
p = 0.0007 by Mann-Whitney U test). ***p < 0.001
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3.20 pg/ml, IQR 2.35–6.40 pg/ml; p = 0.027). IFNγ
levels were substantially elevated in PsA SF (median
6.44 pg/ml, IQR 3.20–14.35 pg/ml) compared with OA
SF (median 3.20 pg/ml, IQR 2.83–4.49 pg/ml; p = 0.015).
CXCL10, IFNγ, and IL-17A levels between patients with
PsA and patients with RA were not significantly different.
Synovial gene expression is concordant with protein levels
In a subset of patients from whom sufficient mRNA
could be obtained, gene expression was quantified in
cells extracted from SF of patients with PsA (n = 30) and
compared with that of patients with OA (n = 4), gout (n
= 6), and RA (n = 5). As shown in Fig. 4, CXCL10 was
tenfold greater (p = 0.007) in patients with PsA than in
patients with OA and 36.2-fold greater than in patients
with gout (p = 2.6 × 10-6). No significant differences in
CXCL10 levels were found between patients with PsA
and patients with RA. There was a significant correlation
between CXCL10 mRNA and protein levels in SF
(Spearman’s correlation coefficient = 0.428, p = 0.02).
A similar finding was obtained for the expression of
CXCR3 in SF cells. CXCR3 was 5.3-fold greater (p= 0.011) in
patients with PsA than in patients with OA, 32.3-fold greater
(p= 1.2 × 10−6) than in patients with gout, and 3.9-fold
greater (p= 0.02) than in patients with RA. IL-17A has previ-
ously been shown to play an important role in the pathogen-
esis of PsA, and anti-IL-17A monoclonal antibodies have
recently been approved for clinical use [17, 18]. IL-17A gene
expression was explored here to gain insight into how the
combination of these cytokines/chemokines acts together in
PsA. IL-17A was found to be 37.5-fold greater (p= 1.5 × 10
−5) in patients with PsA than in those with OA and 19.8-fold
greater (p= 1.7 × 10−4) than in patients with gout. No
significant differences between PsA and RA were found for
IL-17A expression. IFNγ and IL-17A are key effector cyto-
kines of the Th1 and Th17 pathways, respectively. To sup-
port our results of elevated IFNγ and IL-17A in PsA SF, we
also measured the gene Th1- and Th17-specific tran-
scription factors T-bet (TBX21) and RORγt (RORC) in
SF. TBX21 was 5.6-fold greater (p = 0.029) in patients
with PsA than in those with OA and 25-fold greater (p
= 0.0001) than in patients with gout. No significant dif-
ferences between PsA and RA were found for TBX21
expression. RORC was 8.1-fold greater (p = 0.002) in pa-
tients with PsA than in those with OA, 19-fold greater
(p = 0.0001) than in patients with gout, and 3.4-fold
greater than in those with RA (p = 0.037).
CXCL10 expression is higher in SF than in blood
To compare the localized expression of CXCL10 in the
joint with that in the peripheral circulation, we analyzed
expression of CXCL10 and other cytokines in paired SF
and peripheral blood RNA samples of patients with PsA.
In paired SF and blood samples from 11 patients with PsA
(Fig. 5a), mRNA expression of CXCL10 was eightfold
greater (p = 0.035) in SF cells than in whole blood. No sig-
nificant difference in gene expression of IL-17A and
CXCR3 was observed. As shown in Fig. 5b, CXCL10 pro-
tein expression was significantly increased in SF (median
7283.9 pg/ml, IQR 1330–10,362 pg/ml) compared with
serum (median 282.06, IQR 180.7–395.8 pg/ml; p = 0.001).
IFNγ protein levels were significantly reduced (SF me-
dian 6.03 pg/ml, IQR 4.47–8.94 pg/ml; versus serum
median 23.70 pg/ml, IQR 3.2–104.6 pg/ml; p = 0.001),
and no significant differences in IL-17A protein levels
were observed. We also compared the correlation be-
tween CXCL10 and CXCR3 mRNA expression in SF
(Fig. 5c) and blood (Fig. 5d). There was a significant
positive correlation between CXCL10 and CXCR3
mRNA levels in SF (Spearman’s correlation coefficient
= 0.883, p = 0.0031). Interestingly, in some patients (two
of eight total), CXLC10 levels were found to be reduced
in SF compared with serum. Some observations that
may have accounted for this difference included lower
total volume of SF (mean volume 9.0 ml, SD 1.4; versus
33.7 ml, SD 26.5), lower concentration of total nucle-
ated cells in SF (0 × 106 cells/L, SD 0 × 106 cells/L; ver-
sus 9050 × 106 cells/L, SD 4593 × 106 cells/L), and
lower concentration of polymorphonuclear cells in SF
(0.25 × 106 cells/L, SD 0 × 106 cells/L; versus 0.70 × 106
cells/L, SD 0.30 × 106 cells/L). This was not reflected in
clinical indicators of joint inflammation and differences
in blood cell counts, because there were comparable
swollen joint counts (2.5, SD 0.71; versus 2.2, SD 2.3),
tender joint counts (4.0, SD 4.2; versus 2.2, SD 2.2),
blood lymphocytes (1.85 × 10/L, SD 0.07 × 10/L; versus
1.85 × 10/L, SD 0.63 × 10/L), and blood monocytes
Fig. 3 Bar graph of chemokine (C-X-C motif) ligand 10 (CXCL10),
interferon γ (IFNγ), and interleukin (IL)-17A protein expression in
synovial fluid (SF) from 40 patients with psoriatic arthritis (PsA), 14
with osteoarthritis (OA), 8 with gout, and 11 with rheumatoid
arthritis (RA). Error bars indicate SEM. Asterisks are used to indicate
significant differences between groups, where *p < 0.05, **p < 0.01,
and ***p < 0.001 (Mann-Whitney U test). CXCL10 concentration was
converted to nanograms per milliliter
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(0.55 × 10/L, SD 0.07 × 10/L; versus 0.65 × 10/L, SD
0.15 × 10/L) in these patients.
Discussion
PsA is a chronic inflammatory arthritis that is associated
with psoriasis. Within 2 years of the onset of symptoms,
many patients (47%) develop erosive disease, and within
10 years, the majority (88%) of the patients develop ero-
sive disease, which leads to dramatic reduction in their
overall quality of life and functional capabilities and is as-
sociated with an increased mortality rate [19–21]. Disease
activity is a predictor for progression of damage; therefore,
early treatment will help prevent progressive damage in
these patients [22]. Furthermore, initiation of treatment at
an early stage of the disease is associated with better out-
comes [23, 24]. Soluble biomarkers could serve as an ob-
jective measurement tool and could aid in detection of
arthritis in patients with psoriasis and in the general popu-
lation before significant joint damage occurs.
However, the differentiation of PsA from other forms
of arthritis at an early stage can be challenging. Clinic-
ally, it may be difficult to determine whether pain arising
from a joint, tendon, or ligament insertion or from the
spine is related to a biomechanical problem, trauma, an
autoimmunological inflammatory process, or crystal
arthritis [25]. RA and PsA manifest with different symp-
toms clinically in terms of type and symmetry of joint
involvement, joint tenderness, skin and nail involvement,
presence of dactylitis and/or enthesitis, and rheumatoid
factor presence; therefore, it is easier to distinguish the
two conditions by clinical examination. [26]. However,
PsA, OA, and gout may not be as easy to distinguish,
owing to many similarities in presentation, such as distal
interphalangeal joint involvement in both PsA and OA
[27]. Although this is due primarily to bony enlargement
Fig. 4 Bar graph depicting gene expression in synovial fluid (SF) cells of patients with psoriatic arthritis (PsA; n = 30), osteoarthritis (OA; n = 4),
gout (n = 6), and rheumatoid arthritis (RA; n = 5). Error bars indicate SEM. Fold change was calculated using the comparative cycle threshold
(ΔΔCt) method, and values are shown as log102
−ΔCt values to better visualize the difference between groups (see Methods section of main text).
a Interleukin-17A (IL-17A) gene expression was 37.5-fold greater (p = 1.5 × 10−5) in synovial fluid (SF) of patients with PsA than in those with OA
and 19.8-fold greater (p = 1.7 × 10−4) than in those with gout. b Chemokine (C-X-C motif) ligand 10 (CXCL10) gene expression was tenfold greater
(p = 0.007) in SF of patients with PsA than in those with OA and 36.2-fold greater (p = 2.6 × 10−6) than in those with gout. Chemokine (C-X-C
motif) receptor 3 (CXCR3) gene expression was 5.3-fold greater (p = 0.011) in SF of patients with PsA than in those with OA, 32.3-fold greater
(p = 1.2 × 10−6) than in those with gout, and 3.9-fold greater (p = 0.02) than in patients with RA. TBX21 expression was 5.6-fold greater (p = 0.029)
in SF of patients with PsA than in those with OA and 25-fold greater (p = 0.0001) than in patients with gout. RORC gene expression was 8.1-fold
greater (p = 0.002) in SF of patients with PsA than in those with OA, 19-fold greater (p = 0.0001) than in patients with gout, and 3.4-fold greater
(p = 0.037) than in patients with RA. No difference between patients with PsA and patients with RA was found for CXCL10, TBX21, and IL-17A.
Asterisks are used to indicate significant differences between groups, where *p < 0.05, **p < 0.01, and ***p < 0.001. GAPDH Glyceraldehyde
3-phosphate dehydrogenase
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in OA and joint inflammation in PsA, it is difficult for a
nonexpert to distinguish the two. Moreover, some patients
with PsA also have OA, making differentiation impossible
in some patients [28]. In gout, one can also get joint pain
and swelling, as well as redness over the affected joints
and swollen digits, which can look like dactylitis, thus
making it difficult to clinically distinguish from PsA. In
our present study, expression levels of CXCL10 and
CXCR3 were found to be elevated in SF of patients with
PsA as compared with patients with OA and those with
gout. CXCL10 was comparable between patients with PsA
and patients with RA, although CXCR3 was higher in pa-
tients with PsA. The same trend as that for CXCL10 was
observed for the Th1-specific transcription factor T-bet
(TBX21), providing support for increased IFNγ produc-
tion and CXCL10 within PsA SF. This suggests that
Fig. 5 Scatter dot plots of (a) paired synovial fluid (SF) and blood gene expression and (b) protein levels of cytokine expression in patients with
psoriatic arthritis (PsA). Chemokine (C-X-C motif) ligand 10 (CXCL10) gene expression was eightfold greater in SF cells (mean ΔCt = 6.55 ± 2.67) than in
blood cells (mean ΔCt = 9.55 ± 1.44; p = 0.035 by paired Student’s t test; n = 8). Fold change was calculated using the comparative cycle threshold
(ΔΔCt) method, and values are shown as log102
−ΔCt values to better visualize the difference between groups (see Methods section of text). In paired
SF and serum from 11 patients with PsA, CXCL10 levels were significantly elevated in SF, whereas interferon γ (IFNγ) levels were significantly reduced
(p = 0.001 by Wilcoxon signed-rank test). CXCL10 and chemokine (C-X-C motif) receptor 3 (CXCR3) messenger RNA expression were compared in (c) SF
and (d) blood, and a significant positive correlation was observed in SF (Spearman’s correlation coefficient = 0.883, p = 0.0031). Asterisks are used to
indicate significant differences between groups, where * = p<0.05 and ** = p<0.01. GAPDH Glyceraldehyde 3-phosphate dehydrogenase, IL Interleukin
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CXCL10 may play analogous roles in patients with PsA
and patients with RA, but it may distinguish patients with
PsA from those with OA and gout.
Elevated levels of CXCL10 in peripheral fluids have
previously been described as a marker of host immune
response, especially Th1-orientated T cells [29]. CXCL10
was reported to be elevated in several autoimmune dis-
eases, including autoimmune thyroiditis, Graves disease,
type 1 diabetes (T1D), systemic lupus erythematosus
(SLE), localized scleroderma, and RA [29–32]. CXCL10
is present in dermal infiltrate and keratinocytes of active
psoriatic plaques [33, 34] as well as in PsA SF [9]. Proost
et al. reported comparable expression of CXCL10 in SF
from patients with PsA and patients with RA, consistent
with our findings [9]. In serum from patients with PsA
and psoriasis, CXCL10 expression has been reported as
either elevated [33, 35, 36] or unchanged [37, 38] com-
pared with that of control subjects. Differences in sam-
ple sizes and patient characteristics such as disease
duration or use of medications may account for these
conflicting results. In our cohort, we found elevated
CXCL10 in PsA serum compared with that from control
subjects, supporting the use of CXCL10 as a biomarker
for PsA. Our previous report also suggested that
CXCL10 may distinguish patients with PsA from those
with PsC [8].
The role of CXCL10 in PsA pathophysiology has not
been well defined. Serum CXCL10 levels are negatively
correlated to PsA duration [35, 39] and elevated in pa-
tients with psoriasis prior to development of PsA, but
they drop after PsA onset [8]. Similarly, in T1D, serum
CXCL10 levels were high in children and adults, espe-
cially at early stages of the disease, but significantly re-
duced after follow-up. Peripheral blood monocytes and
other leukocytes are the main sources of CXCL10 in pa-
tients with T1D [40]. The chemokine is also highly
expressed in lymphocytes infiltrating into the islet. Upon
stimulation with IFNγ and TNFα, β cells release CXCL9,
CXCL10, and CXCL11 [41]. These chemokines then
promote infiltration of Th1 lymphocytes into the islet
through CXCR3, which releases more IFNγ and TNFα,
thus perpetuating the positive feedback loop. This in
turn leads to the destruction of β cells. In CXCR3-
knockout mice, T1D onset is significantly delayed [42].
In active psoriatic plaques, CXCL10 production has been
found from keratinocytes and dermal infiltrate, and the
migration of NK cells toward CXCL10 has been impli-
cated in psoriasis pathogenesis [33, 43]. In the psoriatic
joint, a similar mechanism may occur whereby activated
CXCR3-expressing Th1 lymphocytes and/or increased
cellular production may be responsible for a concentra-
tion of CXCL10 expression. Attenuation of CXCL10
levels is a consequence of therapies currently approved
for the treatment of psoriasis and PsA, such as the
phosphodiesterase-4 inhibitor apremilast [44] and the
TNFα inhibitor etanercept [45, 46], further supporting a
role for CXCL10 in the pathogenesis of PsA.
When we compared CXCL10 levels in SF to those in
the peripheral circulation, we did observe a dramatic in-
crease in CXCL10 in the majority of patients. In contrast,
IFNγ levels were higher in serum, likely reflecting IFNγ
produced from multiple sources, including psoriatic pla-
ques [42]. Although CXCR3 levels were not significantly
different between SF and peripheral blood cells, there was
also a strong positive correlation between CXCL10 and
CXCR3 mRNA in SF cells, further supporting the notion
that localized CXCR3-producing cells may be responsible
for the concentration of CXCL10 in the SF. In two pa-
tients measured, CXCL10 levels were reduced in SF com-
pared with serum. The lower total SF volume, lower total
nucleated cell count in SF, and lower polymorphonuclear
cells in SF, as well as equivalent levels of total blood
lymphocytes and monocytes, may have contributed to this
difference. These observations could have led to reduced
inflammatory cells overall, including CXCL10-expressing
cells in the SF of these two patients.
Previously, it was thought that PsA is primarily a Th1-
mediated disease; however, in recent years, the IL-17/IL-23
axis has been shown to play an important role in disease
progression and joint damage. IL-17A is an inflammatory
cytokine released from Th17 cells under IL-23 stimulation.
The prominent action of IL-17A is attraction of neutro-
phils to the site of inflammation, generating a powerful
immune response [47]. Coculture of healthy human kerati-
nocytes and activated CD4+ or CD8+ T cells that favor a
Th17 phenotype increased production of CXCL10 from
keratinocytes [48]. Plasma IL-17 levels are also positively
correlated with CXCL10 concentrations in patients with
SLE [49]. These studies suggest CXCL10 production may
be linked to Th17 cell activation. Indeed, similar to what
we saw in CXCL10 and CXCR3 levels, we observed that
mRNA expression and protein levels of IL-17A were com-
parable between PsA and RA samples, in accordance with
reports in the literature, and significantly higher than in
OA and gout SF samples [50]. We also observed higher
mRNA levels of the Th17-specific transcription factor
RORγt (RORC) in PsA SF than in OA, gout, and RA SF,
supporting the involvement of Th17 and a possible link
with CXCL10 in PsA. It should be noted that a signifi-
cant difference in the levels of IL-17A was observed in
patients with PsA who also had gene expression
measurements completed (median 12.45 pg/ml, IQR
6.21–19.39 pg/ml) as compared with those who did not
(3.2 pg/ml, IQR 3.2–7.48 pg/ml; p = 0.01). This sub-
group of patients with PsA was likely responsible for
driving the increased expression of IL-17A in our pa-
tients with PsA, possibly owing to an increase in in-
flammatory cell infiltrate within the SF. Further studies
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are needed to elucidate the relationship between
CXCL10 and the IL-17/IL-23 axis in PsA.
Conclusions
In conclusion, CXCL10 levels are elevated in PsA serum
compared with levels in healthy control subjects, sup-
porting the utility of CXCL10 as a biomarker of PsA sus-
ceptibility. In SF, CXCL10 and IL-17A mRNA and
protein levels are higher in patients with PsA than in
those with OA or gout and similar to those of patients
with RA. Furthermore, CXCL10 expression is significantly
elevated in the SF compared with the peripheral circula-
tion of patients with PsA. These results indicate that
CXCL10 may have an important etiological role in PsA
that is analogous to that in RA, and that it may distinguish
individuals with PsA from patients with OA and gout.
Abbreviations
CASPAR: ClASsification for Psoriatic ARthritis criteria; Ct: Cycle threshold;
CXCL10: Chemokine (C-X-C motif) ligand 10; CXCR3: Chemokine (C-X-C
motif) receptor 3; DMARD: Disease-modifying antirheumatic drug;
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; IFNγ: Interferon γ;
IL: Interleukin; IQR: Interquartile range; mRNA: Messenger RNA; NK: Natural
killer; NSAID: Nonsteroidal anti-inflammatory drug; OA: Osteoarthritis;
PASI: Psoriasis Area Severity Index; PsA: Psoriatic arthritis; PsC: Psoriasis
without psoriatic arthritis; RA: Rheumatoid arthritis; RORγt: RAR-related
orphan receptor γt; SF: Synovial fluid; SLE: Systemic lupus erythematosus;
T1D: type 1 diabetes; Th: T helper cell; TNFα: Tumor necrosis factor α
Funding
The Psoriatic Arthritis Program is supported by a grant from the Krembil
Foundation. AM was supported by an Institute of Musculoskeletal Health and
Arthritis (IMHA) Studentship in Mobility, Musculoskeletal Health and Arthritis
from the Canadian Institutes of Health Research (CIHR). RAP was supported
by a Banting and Best Doctoral Research Award from the CIHR.
Availability of data and materials
The datasets used and/or analyzed during the present study are available
from the corresponding author on reasonable request.
Authors’ contributions
AM and FA participated in study design, experimental work, collection and
analysis of data, interpretation of the results, and preparation of the
manuscript. RAP participated in study design, discussion of results, and
preparation of the manuscript. KL performed additional statistical analysis
and participated in preparation of the manuscript. DDG and VC participated
in study design, interpretation of the results, and preparation of the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the University Health Network Research Ethics
Board according to the principles of the Declaration of Helsinki, and all
participants provided written consent.
Author details
1Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic
Diseases, Krembil Research Institute, University of Toronto, University Health
Network, 399 Bathurst Street 1E-410B, Toronto, ON M5T 2S8, Canada.
2Department of Statistics and Actuarial Science, University of Waterloo,
Waterloo, ON, Canada. 3Division of Rheumatology, Department of Medicine,
University of Toronto, Toronto, ON, Canada. 4Krembil Research Institute,
Toronto Western Hospital, Toronto, ON, Canada. 5Department of Laboratory
Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Received: 2 September 2016 Accepted: 28 November 2016
References
1. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical
pattern of psoriatic arthritis in Germany: a prospective interdisciplinary
epidemiological study of 1511 patients with plaque-type psoriasis.
Br J Dermatol. 2009;160:1040–7.
2. Christophers E, Barker JN, Griffiths CE, Dauden E, Milligan G, Molta C, et al.
The risk of psoriatic arthritis remains constant following initial diagnosis of
psoriasis among patients seen in European dermatology clinics. J Eur Acad
Dermatol Venereol. 2010;24:548–54.
3. Mease PJ, Gladman DD, Helliwell P, Khraishi MM, Fuiman J, Bananis E, et al.
Comparative performance of psoriatic arthritis screening tools in patients
with psoriasis in European/North American dermatology clinics. J Am Acad
Dermatol. 2014;71:649–55.
4. Varada S, Tintle SJ, Gottlieb AB. Apremilast for the treatment of psoriatic
arthritis. Expert Rev Clin Pharmacol. 2014;7:239–50.
5. Taylor WJ. Impact of psoriatic arthritis on the patient: through the lens of
the WHO International Classification of Functioning, Health, and Disability.
Curr Rheumatol Rep. 2012;14:369–74.
6. Haroon M, Kirby B, Fitzgerald O. High prevalence of psoriatic arthritis in
patients with severe psoriasis with suboptimal performance of screening
questionnaires. Ann Rheum Dis. 2013;72:736–40.
7. Mease PJ, Gladman DD, Papp KA, Kraishi MM, Thaci D, Behrens F, et al.
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with
psoriasis in European/North American dermatology clinics. J Am Acad
Dermatol. 2013;69:729–35.
8. Pollock RA, Abji F, Liang K, Chandran V, Pellett FJ, Virtanen C, et al. Gene
expression differences between psoriasis patients with and without
inflammatory arthritis. J Invest Dermatol. 2015;135:620–2.
9. Proost P, Struyf S, Loos T, Gouwy M, Schutyser E, Conings R, et al.
Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by
synergizing inflammatory cytokines: CXCL8 and CXCL10 are discriminative
markers for autoimmune arthropathies. Arthritis Res Ther. 2006;8:R107.
10. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, et al.
Chemokine receptor specific for IP-10 and Mig: structure, function, and
expression in activated T-lymphocytes. J Exp Med. 1996;184:963–9.
11. Cassatella MA, Gasperini S, Calzetti F, Bertagnin A, Luster AD, McDonald PP.
Regulated production of the interferon-γ-inducible protein-10 (IP-10)
chemokine by human neutrophils. Eur J Immunol. 1997;27:111–5.
12. Gasperini S, Marchi M, Calzetti F, Bertagnin A, Luster AD, McDonald PP. Gene
expression and production of the monokine induced by IFN-γ (MIG), IFN-
inducible T cell alpha chemoattractant (I-TAC), and IFN-γ-inducible protein-10
(IP-10) chemokines by human neutrophils. J Immunol. 1999;162:4928–37.
13. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine
receptors in T-cell priming and Th1/Th2-mediated responses. Immunol
Today. 1998;19:568–74.
14. Abji F, Pollock RA, Liang K, Chandran V, Gladman DD. CXCL10 is a possible
biomarker for the development of psoriatic arthritis among patients with
psoriasis. Arthritis Rheumatol. 2016;68:2911–6.
15. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al.
Classification criteria for psoriatic arthritis: development of new criteria from
a large international study. Arthritis Rheum. 2006;54:2665–73.
16. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative
CT method. Nat Protoc. 2008;3:1101–8.
17. Helliwell P, Coates L. Interleukin-17 inhibition in psoriatic arthritis. Lancet.
2015;386:1114–6.
18. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in
patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–46.
19. Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol. 2008;26(5
Suppl 51):S62–5.
20. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and
radiological study of early psoriatic arthritis: an early synovitis clinic
experience. Rheumatology (Oxford). 2003;42:1460–8.
Muntyanu et al. Arthritis Research & Therapy  (2016) 18:296 Page 9 of 10
21. Touma Z, Thavaneswaran A, Chandran V, Pellett F, Cook R, Gladman D.
Clinical and demographic characteristics of erosion-free and erosion-present
status in psoriatic arthritis in a prospective cohort study. J Rheumatol.
2016;43:1057–62.
22. Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological
damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis.
2007;66:370–6.
23. Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with
psoriatic arthritis who present early fare better than those presenting later
in the disease? Ann Rheum Dis. 2011;70:2152–4.
24. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than
6 months contributes to poor radiographic and functional outcome in
psoriatic arthritis. Ann Rheum Dis. 2015;74:1045–50.
25. Mease PJ. Inflammatory musculoskeletal disease: identification and
assessment. J Rheumatol. 2011;38:557–61.
26. Gladman DD. Clinical, radiological, and functional assessment in psoriatic
arthritis: is it different from other inflammatory joint diseases? Ann Rheum
Dis. 2006;65 Suppl 3:iii22–4.
27. Tan AL, Grainger AJ, Tanner SF, Emery P, McGonagle D. A high-resolution
magnetic resonance imaging study of distal interphalangeal joint
arthropathy in psoriatic arthritis and osteoarthritis: are they the same?
Arthritis Rheum. 2006;54:1328–33.
28. McGonagle D, Hermann KA, Tan AL. Differentiation between
osteoarthritis and psoriatic arthritis: implications for pathogenesis and
treatment in the biologic therapy era. Rheumatology (Oxford). 2015;54:
29–38.
29. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P.
Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.
Autoimmun Rev. 2014;13:272–80.
30. Antonelli A, Ferri C, Ferrari SM, Colaci M, Fallahi P. Immunopathogenesis of
HCV related endocrine manifestations in chronic hepatitis and mixed
cryoglobulinemia. Autoimmun Rev. 2008;8:18–23.
31. Antonelli A, Fallahi P, Ferrari SM, Pupilli C, d’Annunzio G, Lorini R, et al.
Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with
newly diagnosed type 1 diabetes: a longitudinal study. Diabet Med. 2008;25:
1349–53.
32. Magee KE, Kelsey CE, Kurzinski KL, Ho J, Mlakar LR, Feghali-Bostwick CA, et
al. Interferon-γ inducible protein-10 as a potential biomarker in localized
scleroderma. Arthritis Res Ther. 2013;15:R188.
33. Gottlieb AB, Luster AD, Posnett DN, Carter DM. Detection of a γ interferon-
induced protein IP-10 in psoriatic plaques. J Exp Med. 1988;168:941–8.
34. Boorsma DM, Flier J, Sampat S, Ottevanger C, de Haan P, Hooft L, et al.
Chemokine IP-10 expression in cultured human keratinocytes. Arch
Dermatol Res. 1998;290:335–41.
35. Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S,
et al. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with
psoriatic arthritis. Clin Exp Rheumatol. 2009;27:22–7.
36. Ekman AK, Sigurdardottir G, Carlström M, Kartul N, Jenmalm MC, Enerback
C. Systemically elevated Th1-, Th2- and Th17-associated chemokines in
psoriasis vulgaris before and after ultraviolet B treatment. Acta Derm
Venereol. 2013;93:527–31.
37. Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF, et al.
Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-
citrulline autoreactivity is associated with up regulation of proinflammatory
cytokines. Ann Rheum Dis. 2007;66:712–9.
38. Lima XT, Oliveira RT, Braga FG, Magalhaes RF, Mamoni RL, Blotta MH.
Circulating levels of chemokines in psoriasis. Autoimmunity. 2015;48:57–60.
39. Devito A. Interferon γ-induced chemokines in psoriatic arthritis. Clin Ter.
2014;165:e442–6.
40. Antonelli A, Ferrari SM, Corrado A, Ferrannini E, Fallahi P. CXCR3, CXCL10
and type 1 diabetes. Cytokine Growth Factor Rev. 2014;25:57–65.
41. Frigerio S, Junt T, Lu B, Gerard C, Zumsteg U, Holländer GA, et al. β cells are
responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med.
2002;8:1414–20.
42. Maeda S, Hayami Y, Naniwa T, Ueda R. The Th17/IL-23 axis and natural
immunity in psoriatic arthritis. Int J Rheumatol. 2012;2012:539683.
43 Ottaviani C, Nasorri F, Bedini C, de Pità O, Girolomoni G, Cavani A.
CD56brightCD16− NK cells accumulate in psoriatic skin in response to
CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol.
2006;36:118–28.
44 Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al.
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-
inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol.
2010;159:842–55.
45 Ichikawa T, Kageyama Y, Kobayashi H, Kato N, Tsujimura K, Koide Y.
Etanercept treatment reduces the serum levels of interleukin-15 and
interferon-γ inducible protein-10 in patients with rheumatoid arthritis.
Rheumatol Int. 2010;30:725–30.
46 Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, et al.
TNF inhibition rapidly down-regulates multiple proinflammatory pathways
in psoriasis plaques. J Immunol. 2005;175:2721–9.
47 Frleta M, Siebert S, McInnes IB. The interleukin-17 pathway in psoriasis and
psoriatic arthritis: disease pathogenesis and possibilities of treatment.
Curr Rheumatol Rep. 2014;16:414.
48 Peters JH, Tjabringa GS, Fasse E, de Oliveira VL, Schalkwijk J, Koenen HJ, et
al. Co-culture of healthy human keratinocytes and T-cells promotes
keratinocyte chemokine production and RORγt-positive IL-17 producing
T-cell populations. J Dermatol Sci. 2013;69:44–53.
49 Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-
23 and IL-17 in patients with systemic lupus erythematosus: implications for
Th17-mediated inflammation in auto-immunity. Clin Immunol. 2008;127:
385–93.
50 Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis.
Clin Rev Allergy Immunol. 2013;44:183–93.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Muntyanu et al. Arthritis Research & Therapy  (2016) 18:296 Page 10 of 10
